MET and non-small cell lung carcinoma: For this reason, crizotinib was the first drug approved by the FDA in 2018 for the treatment of advanced NSCLC in MET exon 14 skipping alterations-positive NSCLC patients or with tumor recurrence after first-line platinum-based chemotherapy [145].